The primary aim of the study is to discuss the potential interactions between venetoclax and common drugs used in department of hematology and the corresponding effects on the efficacy and safety of venetoclax treatment. Here, we report an acute myeloid leukemia patient treated with venetoclax and posaconazole, and the dose of venetoclax was adjusted due to drug interactions. Clinical pharmacists actively participated in treatment of this patient to provide pharmacy care to assist clinicians to identify the venetoclax-induced liver function impairment and give timely management. The case reported here is hoped to provide reference for clinical venetoclax treatment in patients with such disease. Clinical pharmacists should actively participate in clinical treatment, actively screen potential drug interactions, strengthen cooperation and communication with doctors, provide patients with high-quality pharmaceutical services, and establish clinical pharmacists' status in the multidisciplinary treatment of tumor.

中文翻译：

---

由于药物相互作用而调整维奈托克剂量：病例报告和文献综述。

该研究的主要目的是讨论 Venetoclax 与血液科常用药物之间的潜在相互作用以及对 Venetoclax 治疗的疗效和安全性的相应影响。在此，我们报道了一名急性髓系白血病患者接受维奈托克和泊沙康唑治疗，由于药物相互作用而调整了维奈托克的剂量。临床药师积极参与该患者的治疗，提供药学护理，协助临床医生识别维奈托克引起的肝功能损害并及时给予处理。本文报道的病例希望为该病患者的临床维奈托克治疗提供参考。临床药师应积极参与临床治疗，积极筛选潜在的药物相互作用，加强与医生的合作与沟通，为患者提供优质的药学服务，树立临床药师在肿瘤多学科治疗中的地位。